Reunion Neuroscience is focused on developing innovative serotonergic psychedelic therapies aimed at addressing mental health disorders, particularly postpartum depression (PPD) and adjustment disorders. Their lead candidate, RE104, is a patented prodrug of 4-OH-DiPT, a compound similar to psilocybin, which targets the serotonin 2A receptor (5HT2AR). This approach is based on extensive research indicating that psychedelics can provide rapid and durable therapeutic effects, often requiring only a single dose, in contrast to traditional treatments like SSRIs that may have limited efficacy and prolonged dosing requirements. The company is currently conducting the RECONNECT Phase 2 clinical trial to evaluate the safety and effectiveness of RE104 in treating moderate to severe PPD.

In addition to PPD, Reunion Neuroscience is exploring the potential of RE104 for other psychiatric conditions, including adjustment disorders in cancer patients. Their research highlights the significant unmet need for effective, fast-acting treatments in these populations, as existing therapies often fall short in terms of efficacy and safety. The RE200 series of drug candidates, which are structurally similar to classical psychedelics, are also being developed to selectively target the serotonin 2A receptor without off-target effects. Overall, Reunion Neuroscience aims to transform mental health treatment by leveraging the therapeutic potential of psychedelics to create safer and more effective solutions for underserved patient populations.

United States

Reunion Neuroscience is a clinical stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.

Reunion Neuroscience

Company Details